Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Recruiting 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Neoplasm Metastasis 1Abiraterone Acetate 1

Interventions

Cyclophosphamide 4trastuzumab deruxtecan 3fludarabine 3Standard of Care 3Injections 3Cisplatin 3Bevacizumab 3toripalimab 2sacituzumab govitecan 2pembrolizumab 2fludarabine phosphate 2Specimen Handling 2Radiosurgery 2Pemetrexed 2Palliative Care 2Gemcitabine 2Fulvestrant 2Fluorouracil 2Docetaxel 2130-nm albumin-bound paclitaxel 2zimberelimab 1vedolizumab 1tislelizumab 1sintilimab 1lobaplatin 1lenvatinib 1ivosidenib 1irinotecan sucrosofate 1exemestane 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasm Metastasis × Abiraterone Acetate × Clear all
NCT05422911 2022-06-21

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

James J. Peters Veterans Affairs Medical Center

Phase 2 Not yet recruiting
200 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡